The Smart Investor
    Facebook Instagram
    Monday, July 27
    Facebook Instagram LinkedIn
    The Smart Investor
    • Home
    • About
      • About Us
      • Careers
    • Smart Investing
      • Getting Started
      • Investing Strategy
      • Smart Analysis
      • Smart Reads
    • US Stocks
    • Special Free Reports!
    • As Featured on BT
    • Our Services
      • Our Services
      • Subscribe now!
    • Login
    • Cart
    The Smart Investor
    Home»Dividend Stocks»4 US Stocks Delivering an Attractive Mix of Growth and Dividends
    Dividend Stocks

    4 US Stocks Delivering an Attractive Mix of Growth and Dividends

    Looking for a sweet combination of growth and passive income? These four stocks may be suitable for you.
    Royston Y.By Royston Y.April 22, 20255 Mins Read
    Facebook Twitter LinkedIn Email WhatsApp
    Image credit: Walmart website
    Share
    Facebook Twitter LinkedIn Email WhatsApp

    Growth stocks are great for increasing the value of your investment portfolio and better preparing yourself for retirement.

    However, cash inflows are also important when you retire, and dividends can help to ease that transition.

    Hence, it makes sense to try to get the best of both worlds by searching for stocks with growth and increasing dividends.

    Here are four such US stocks that can deliver on this promise.

    Lancaster Colony (NASDAQ: LANC)

    Lancaster Colony is a manufacturer and marketer of speciality food products for the retail and foodservice channels.

    Some brands under the company include Marzetti dips and dressings, Sister Shubert’s homemade rolls, and New York Brand bakery bread and croutons.

    Lancaster Colony saw its revenue for the first half of fiscal 2025 (1H FY2025) ending 31 December 2024 rise 3% year on year to US$975.9 million.

    Operating profit increased by 7.3% year on year to US$131.5 million.

    Net profit (excluding a pension settlement charge of US$14 million) increased by 12.8% year on year to S$107.7 million.

    The company also generated a positive free cash flow of US$98.9 million, albeit 5.3% lower than the previous year’s US$104.4 million.

    A quarterly dividend of US$0.95 was declared, marking the 62nd consecutive year of dividend increase for the business.

    Lancaster Colony is just one of 12 companies in the US with such a stellar dividend track record.

    Management is continuing with strategic growth initiatives for FY2025 with the successful implementation of a new ERP system.

    By stabilising its supply chain, Lancaster Colony can now focus on value creation and growth initiatives.

    It has also successfully integrated its recently acquired sauce and dressing production facility in Atlanta, Georgia.

    This acquisition, costing around US$75 million, adds approximately 250,000 square feet of manufacturing space and is located closer to certain core customers.

    Colgate-Palmolive (NYSE: CL)

    Colgate-Palmolive is a consumer goods company that manufactures and sells a wide range of oral care, personal care, and home care products in more than 200 countries.

    Some of its famous brands include Colgate, Palmolive, Protex, Sanex, and Ajax.

    For 2024, the company’s revenue rose 3.3% year on year to US$20.1 billion.

    Operating profit climbed 7.1% year on year to US$4.3 billion while net profit surged 25.6% year on year to US$2.9 billion.

    Free cash flow improved from US$3 billion last year to US$3.5 billion in 2024, up 16.6% year on year.

    In line with its consistent and increasing free cash flow generation, Colgate-Palmolive upped its quarterly cash dividend from US$0.50 to US$0.52.

    The directors also authorised a new share repurchase programme of up to US$5 billion.

    For 2025, the company expects total sales to remain flat but that organic growth will be in the range of 3% to 5%.

    This growth will be negated by the company’s planned exit from the private label pet nutrition business.

    Back in February 2025, Colgate-Palmolive acquired Care TopCo Pty Ltd, owner of the Prime100 pet food brand.

    This purchase allows the company to enter the fresh pet food category and strengthens its presence in the Australian pet food market.

    Walmart (NYSE: WMT)

    Walmart is an omnichannel retailer with 10,750 stores and numerous e-commerce sites spread across 19 countries.

    The company serves around 270 million customers and employs more than 2.1 million staff worldwide.

    The retailer delivered an impressive performance for its fiscal 2025 (FY2025) ending 31 January 2025.

    Total revenue rose 5.1% year on year to US$681 billion while operating income increased by 8.6% year on year to US$29.3 billion.

    Net profit climbed 25.3% year on year to US$19.4 billion, largely due to a US$3 billion loss recognised in FY2024.

    Stripping out this exceptional item, net profit would have increased by 9.1% year on year to US$20.2 billion.

    Walmart also generated a positive free cash flow of US$12.7 billion for FY2025.

    In line with the good results, the retailer increased its quarterly dividend by 13% year on year from US$0.83 to US$0.94 per share, making this the 52nd consecutive year of increase.

    For FY2026, Walmart expects net sales to increase by 3% to 4% year on year, with diluted earnings per share projected to come in between US$2.50 to US$2.60.

    At the midpoint, this represents a year-on-year increase of 5.8%.

    Abbott Labs (NYSE: ABT)

    Abbott Labs is a healthcare company with a portfolio of products and technologies in diagnostics, medical devices, nutritional, and branded generic medicine.

    The company employs 114,000 staff spread across more than 160 countries.

    Net sales for the first quarter of 2025 (1Q 2025) rose 4% year on year to US$10.4 billion.

    Operating profit jumped 22.1% year on year to US$1.7 billion while net profit improved by 8.2% year on year to US$1.3 billion.

    In tandem with these good results, the healthcare company increased its quarterly dividend by 7.3% year on year to US$0.59,

    This increase marks Abbott’s 53rd consecutive year of dividend growth, with its dividend increasing by more than 60% since 2020.

    Last month, the company announced that the US Food and Drug Administration (FDA) had approved an investigational device exemption for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the treatment of severe calcification in coronary arteries before stenting.

    This IVL System represents a potential new treatment by using sound pressure waves to treat arterial calcium blockages.

    Just a few days later, Abbott received the CE Mark in Europe for its Volt PFA System to treat patients battling atrial fibrillation.

    Big Tech is spending hundreds of billions on AI,  and the ripple effects are just beginning. Our new investor guide shows how AI is changing the way companies generate revenue, structure their business models, and gain an edge. Even if you already know the major players, this report reveals something far MORE important: The why and how behind their moves, and what it means for your portfolio. Download your free report now.

    Follow us on Facebook and Telegram for the latest investing news and analyses!

    Disclosure: Royston Yang does not own shares in any of the companies mentioned.

    Yahoo
    Share. Facebook Twitter LinkedIn Email WhatsApp

    Related Posts

    The Smart Investor Smart Reads Pic 8

    Smart Reads of the Week: Passive Income, Singapore Dividend Stocks, and REIT Growth Opportunities

    July 26, 2026

    Top Stock Market Highlights of the Week: Metro Holdings, Singapore Exchange, Mi Technovation and Singapore’s Inflation

    July 25, 2026
    bull market, stock market up

    Get Smart: The Biggest Risk When The STI is at a Record High

    July 24, 2026
    Facebook Instagram LinkedIn Telegram
    • Careers
    • Disclaimer & Privacy Policy
    • Advertising & Media Enquiries
    • Subscription Terms of Service
    © 2026 The Smart Investor. All Rights Reserved. The Smart Investor, thesmartinvestor.com.sg, an investment education website managed by The Investing Hustle Pte Ltd (Company Reg No. 201933459Z) is not licensed or otherwise regulated by the Monetary Authority of Singapore, and in particular, is not licensed or regulated to carry on business in providing any financial advisory service. Accordingly, any information provided on this site is meant purely for informational and investor educational purposes and should not be relied upon as financial advice. No information is presented with the intention to induce any reader to buy, sell, or hold a particular investment product or class of investment products. Rather, the information is presented for the purpose and intentions of educating readers on matters relating to financial literacy and investor education. Accordingly, any statement of opinion on this site is wholly generic and not tailored to take into account the personal needs and unique circumstances of any reader. The Smart Investor does not recommend any particular course of action in relation to any investment product or class of investment products. Readers are encouraged to exercise their own judgment and have regard to their own personal needs and circumstances before making any investment decision, and not rely on any statement of opinion that may be found on this site.

    Type above and press Enter to search. Press Esc to cancel.